LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
STANDARD BIOTOOLS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.64+0.01 (+2.27%)
Close on Oct 19, 2026
- Market cap
- $251.45M
- P/E (TTM)
- 2.9
- Dividend yield
- –
STANDARD BIOTOOLS INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | – | – | – | – | – | $36.84M | $34.57M | $28.21M | $36.18M | $16.59M | $14.01M | – | – |
| Genomics | – | – | – | – | – | – | $9.88M | $10.40M | $9.00M | $9.36M | $11.60M | $11.36M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics | – | – | – | – | – | – | -$13.41M | -$10.21M | -$23.74M | -$14.54M | -$5.11M | -$7.11M | – |
| Genomics | – | – | – | – | – | – | $517.00K | $1.93M | $952.00K | -$196.00K | -$147.00K | $301.00K | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $14.52M | $15.45M | $17.41M | $13.80M | $15.67M | $14.78M | $18.44M | $15.78M | $15.89M | $23.59M | $21.38M | $18.71M | 72.2% | -7.4% |
| Consumables | $9.39M | $10.98M | $8.95M | $8.71M | $10.46M | $8.14M | $10.77M | $10.51M | $8.85M | $17.31M | $10.44M | $9.71M | 46.7% | -10.3% |
| Services and other revenue | $5.59M | $5.69M | $6.39M | $5.75M | $6.09M | $5.44M | $6.34M | $6.31M | $6.60M | – | $6.80M | $6.66M | 27.8% | -8.2% |
| Services and other revenue | $5.59M | $5.69M | $6.39M | $5.75M | $6.09M | $5.44M | $6.34M | $6.31M | $6.60M | – | – | – | 27.8% | -8.2% |
| Instruments | $5.13M | $4.47M | $8.46M | $5.10M | $5.22M | $6.65M | $7.67M | $5.27M | $7.05M | $6.29M | $10.95M | $9.00M | 25.5% | -1.6% |
| Service revenue | – | – | – | – | – | $17.61M | $21.62M | $24.44M | $14.05M | $21.03M | $6.71M | $6.57M | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $92.00K | $90.00K | – | – |
| Product and service revenue | – | – | – | – | – | $39.84M | $44.84M | $44.03M | $36.22M | $44.62M | $28.10M | $25.28M | – | – |
| Collaboration and other revenue | – | – | – | – | – | $956.00K | $1.88M | $938.00K | $989.00K | $921.00K | $92.00K | $90.00K | – | – |
| Instrument support services | – | – | – | – | – | $5.50M | $5.91M | $6.19M | $6.37M | $6.17M | $6.57M | $6.45M | – | – |
| Assay services | – | – | – | – | – | $12.11M | $15.70M | $18.25M | $7.68M | $14.86M | $142.00K | $114.00K | – | – |
| Somascan assay kits and related | – | – | – | – | – | – | – | – | $6.27M | $8.28M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $8.62M | $9.36M | $10.72M | $7.25M | $9.13M | $8.90M | $9.44M | $8.88M | $9.07M | $12.52M | $8.77M | $8.16M | 42.9% | -5.5% |
| Americas | $7.65M | $7.75M | $6.96M | $7.84M | $8.69M | $7.07M | $10.03M | $9.76M | $9.17M | $24.66M | $13.22M | $10.87M | 38.0% | -12.0% |
| Asia-Pacific | $3.84M | $4.04M | $6.11M | $4.47M | $3.95M | $4.26M | $5.30M | $3.45M | $4.26M | $8.36M | $6.20M | $6.34M | 19.1% | -2.8% |
| China | – | – | – | – | – | – | – | – | – | – | – | $4.50M | – | – |
From the segment and revenue-disaggregation notes of Standard Biotools's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.